Technological Advancement in UK Pharma Industry will Escalate the UK Peptide Therapeutics Market

Published: Nov 2020

The UK peptide therapeutics market will see a considerable growth of 3.7% during the forecast period. Well established healthcare infrastructure is also one of the key reasons which are expected to promote the acceptance of peptide therapeutics in the UK for the treatment of various health conditions, such as CVD, cancer, and others. The market players in the UK are focusing on the integration of novel technologies, to enhance the treatment of peptide therapeutics in the country.

  • Spotlight on liquid chromatography key techniques for peptide purification and applications for development and commercial peptides.
  • Strategies for peptide half-life extension including updating the GLP-1 field and techniques on improving the delivery of peptides.
  • Achieving peptide optimization by improving physical and chemical stability, permeability, and bioavailability.

Browse the full report description of "UK Peptide Therapeutics Market Size, Share & Trends Analysis Report, By Route of Administration (Oral and Parenteral), by Application (Cancer, Metabolic Disorder, Gastrointestinal Disorders, Central Nervous System Disorders, Respiratory Disorders, and Others), Forecast 2020-2026" at https://www.omrglobal.com/industry-reports/uk-peptide-therapeutics-market

The significant prevalence of cancer and respiratory disorders in the UK has led the players to invest in the R&D of new technologies to promote the effective treatment of cancer across the country. For instance, in February 2020, Genentech in partnership with Bicycle Therapeutics entered a drug discovery in cancer research for the clinical-stage biotech. Bicycle Therapeutics is a Cambridge based company, developing a new class of drugs comprised of peptides, which are chains of amino acids. The partnership covers up to 4 drugs that are used to treat multiple immuno-oncology targets. 

Market Coverage

Report Elements

Details

Study Period

2019-2026

Base year

2019

Forecast period

2020-2026

Segments Covered

By Route of Administration and By Application

Key Companies Profiled

Novo Nordisk A/S, AstraZeneca Plc, GlaxoSmithKline PLC, Sanofi SA, and Novartis International AG


Key questions addressed by the report

  • What is the market growth rate during the forecast period?
  • Which segment dominates the market in the base year?
  • Which segment will project the fastest growth in the market during the forecast period?
  • How COVID-19 will impact the market growth in 2020 and coming years?

o Recovery Timeline

o Deviation from pre-COVID-19

o Most affected segment

o Recommendations  

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

UK Peptide Therapeutics Market – Segmentation

By Route of Administration

  • Oral
  • Parenteral

By Application

  • Cancer
  • Metabolic Disorder
  • Gastrointestinal Disorders
  • Central Nervous System Disorders
  • Respiratory Disorders
  • Others (Kidney Disorder and Autoimmune Disorder)
To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/uk-peptide-therapeutics-market